Sezary Syndrome Clinical Trials

52 clinical trials for Sezary Syndrome across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma — RECRUITING · PHASE1
• Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome — RECRUITING · PHASE2
• A Registry for People With T-cell Lymphoma — RECRUITING
• Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients — RECRUITING · PHASE2
• Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research — RECRUITING
• Extracorporeal Photopheresis in Sezary Syndrome — RECRUITING
• Tissue Repository: CTCL Collection Protocol — RECRUITING
• Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance — RECRUITING
• Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. — RECRUITING
• Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers — ACTIVE_NOT_RECRUITING · PHASE2
• Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma — SUSPENDED · PHASE2
• Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies — SUSPENDED · PHASE1
• Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome — ACTIVE_NOT_RECRUITING · PHASE2
• Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL — ACTIVE_NOT_RECRUITING · PHASE1
• Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome — ACTIVE_NOT_RECRUITING · PHASE1
• Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma — NOT_YET_RECRUITING · PHASE1
• Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD) — NOT_YET_RECRUITING
• Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment — TERMINATED · PHASE1
• A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) — NOT_YET_RECRUITING · PHASE1
• Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides — COMPLETED · PHASE2
• Ritlecitinib in CTCL — TERMINATED · PHASE2
• Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab — COMPLETED · PHASE2
• Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) — COMPLETED · PHASE2
• Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides — TERMINATED · PHASE1
• VircapSeq Virus Detection in Sézary Syndrome — COMPLETED
• Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome — COMPLETED · PHASE1
• Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma — COMPLETED · PHASE2
• Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome — COMPLETED · PHASE1
• Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL — TERMINATED · PHASE3
• Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies — COMPLETED · PHASE1
• AEDV Registry of Primary Cutaneous Lymphoma — OTHER
• A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat — COMPLETED · PHASE1
• Evolution of the SURvival of Patients With SEzary Syndrome (SS) Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies — OTHER
• Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma — TERMINATED · PHASE2
• Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma — COMPLETED · PHASE1
• Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma — COMPLETED · NA
• TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome — COMPLETED · PHASE1
• Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas — WITHDRAWN · PHASE1
• NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) — OTHER · PHASE2
• Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome — TERMINATED · PHASE4
• Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) — COMPLETED · PHASE2
• Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level — COMPLETED · PHASE2
• A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) — COMPLETED · PHASE2
• Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL — COMPLETED · PHASE2
• Effect of Denileukin Diftitox on Immune System in CTCL Patients — COMPLETED
• Immunization Against Tumor Cells in Sezary Syndrome — COMPLETED · PHASE2
• In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL) — COMPLETED
• Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma — COMPLETED · NA
• Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome — TERMINATED · PHASE3
• Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients — COMPLETED · PHASE4

Refine this search